These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15564008)

  • 41. Mandatory rubella immunity program among New Mexico Health staff.
    Mann JM; Montes J
    Am J Public Health; 1982 Aug; 72(8):855-6. PubMed ID: 7091486
    [No Abstract]   [Full Text] [Related]  

  • 42. [Antibody development and frequency of events temporarily associated with measles and rubella vaccines among university health personnel in Jalisco].
    Villaseñor-Sierra A; Santos-Preciado JI; Alvarez-y-Muñoz MT; Rivas-García ME; Martínez-Sandoval F; Falcón-Franco MA
    Gac Med Mex; 2005; 141(6):455-9. PubMed ID: 16381498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rubella immunisation.
    Paul C
    N Z Med J; 1980 Dec; 92(673):440. PubMed ID: 6937787
    [No Abstract]   [Full Text] [Related]  

  • 44. [Rubella in Poland in 2005].
    Czarkowski MP; Stefanoff P
    Przegl Epidemiol; 2007; 61(2):199-206. PubMed ID: 17956032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efforts toward Rubella elimination and improved quality of health care services.
    Pagani L; Guala A; Campra D; Paoletti R; Leonardi G; Pastore G
    Clin Infect Dis; 2005 Apr; 40(8):1208-9. PubMed ID: 15791526
    [No Abstract]   [Full Text] [Related]  

  • 46. Prevalence of HI antibody titer against rubella virus to determine the effect of mass vaccination in Tehran.
    Soleimanjahi H; Bamdad T; Fotouhi F; Roustai MH; Faghihzadeh S
    J Clin Virol; 2005 Oct; 34(2):153-4. PubMed ID: 16076562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement.
    Reef SE; Cochi SL
    Clin Infect Dis; 2006 Nov; 43 Suppl 3():S123-5. PubMed ID: 16998770
    [No Abstract]   [Full Text] [Related]  

  • 48. Elimination of rubella from the United States: a milestone on the road to global elimination.
    Meissner HC; Reef SE; Cochi S
    Pediatrics; 2006 Mar; 117(3):933-5. PubMed ID: 16510677
    [No Abstract]   [Full Text] [Related]  

  • 49. Seroprevalence of rubella among Jordanian women of childbearing age.
    Jarour N; Hayajneh WA; Balbeesi A; Otoom H; Al-Shurman A; Kharabsheh S
    Vaccine; 2007 May; 25(18):3615-8. PubMed ID: 17280747
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The rubella problem in Hawaii.
    Halstead SB
    Hawaii Med J; 1969; 28(5):387-8. PubMed ID: 5791180
    [No Abstract]   [Full Text] [Related]  

  • 51. Low postpartum rubella vaccination rates in high-risk women, Miami, Florida, 2001.
    Bloom SA; Trepka MJ; Nobles RE; Becerra MA; Reef S; Zhang G
    Am J Prev Med; 2006 Feb; 30(2):119-24. PubMed ID: 16459209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rubella immunization in Malaysia--20 years on, and the challenges ahead.
    Narimah A
    Med J Malaysia; 2005 Aug; 60(3):267-8. PubMed ID: 16379177
    [No Abstract]   [Full Text] [Related]  

  • 53. Factors associated with low immunity to rubella infection on antenatal screening.
    Sathanandan D; Gupta L; Liu B; Rutherford A; Lane J
    Aust N Z J Obstet Gynaecol; 2005 Oct; 45(5):435-8. PubMed ID: 16171483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Fioredda F; Giacchino M; Castagnola E
    Cancer; 2005 Apr; 103(8):1758-9; author reply 1760. PubMed ID: 15717298
    [No Abstract]   [Full Text] [Related]  

  • 55. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Laws HJ; Calaminus G; Göbel U
    Cancer; 2005 Apr; 103(8):1759; author reply 1760. PubMed ID: 15717299
    [No Abstract]   [Full Text] [Related]  

  • 56. Rubella susceptibility in south Arkansas.
    Elliott WG
    J Ark Med Soc; 1982 Jun; 79(1):56-7. PubMed ID: 6213599
    [No Abstract]   [Full Text] [Related]  

  • 57. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rubella elimination programme strengthened through measles elimination programme in Catalonia.
    Domínguez A; Torner N; Martínez A; Costa J; Plans P; Ciruela P; Salleras L
    Vaccine; 2006 Feb; 24(9):1433-7. PubMed ID: 16226357
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Controlling rubella and hepatitis.
    Cantu BJ
    Calif Nurse; 1982 Dec; 78(6):4. PubMed ID: 6925452
    [No Abstract]   [Full Text] [Related]  

  • 60. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
    Yerkovich ST; Rowe J; Richmond P; Suriyaarachchi D; Heaton T; Hollams E; Ladyman C; Serralha M; Sadowska A; Loh R; Wesselingh SL; Sly PD; Holt PG
    Vaccine; 2007 Feb; 25(10):1764-70. PubMed ID: 17224218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.